The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Open accessAbstract
Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically through some deleterious effects of anticancer treatment on CV health. Anticancer therapies can cause a wide spectrum of short- and long-term cardiotoxic effects. An explosion of novel cancer therapies has revolutionised this field and dramatically altered cancer prognosis. Nevertheless, these new therapies have introduced unexpected CV complications beyond heart failure. Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment. This ESMO consensus article proposes to define CV toxicities related to cancer or its therapies and provide guidance regarding prevention, screening, monitoring and treatment of CV toxicity. The majority of anticancer therapies are associated with some CV toxicity, ranging from asymptomatic and transient to more clinically significant and long-lasting cardiac events. It is critical however, that concerns about potential CV damage resulting from anticancer therapies should be weighed against the potential benefits of cancer therapy, including benefits in overall survival. CV disease in patients with cancer is complex and treatment needs to be individualised. The scope of cardio-oncology is wide and includes prevention, detection, monitoring and treatment of CV toxicity related to cancer therapy, and also ensuring the safe development of future novel cancer treatments that minimise the impact on CV health. It is anticipated that the management strategies discussed herein will be suitable for the majority of patients. Nonetheless, the clinical judgment of physicians remains extremely important; hence, when using these best clinical practices to inform treatment options and decisions, practitioners should also consider the individual circumstances of their patients on a case-by-case basis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to the cumulative cisplatin dose, peak drug exposure, young age at treatment, co-administration of other ototoxic drugs and others are well-defined risk factors for more severe auditory damage 167,168,169 .”
From Osteosarcoma (2022) · cites this paper as [167]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
Self-citation2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Self-citationSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citationStone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Cited by
Sorted by citations
Items 201–300 of 999
Mauro, C., Capone, V., Cocchia, R., Cademartiri, F., Riccardi, F., Arcopinto, M., Alshahid, M., Anwar, K., Carafa, M., Carbone, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062121 · Cited by 21
Sung, H., Hyun, N., Ohman, R. E., Yang, E. H., Siegel, R. L., & Jemal, A. (2023) · International Journal of Epidemiology · doi:10.1093/ije/dyad097 · Cited by 21
AC-Mode of Chemotherapy as a Trigger of Cardiac Syndrome X: A Case Study
Арманович, А. А., Mkrtchyan, L., Abrahomovich, O., Sheibani, M., Guevorkian, A. G., Sarrafzadegan, N., Kozhukhov, S., Agati, L., Astengiano, R., Zaritska, V., et al. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.100994 · Cited by 21
ARTIFICIAL INTELLIGENCE, PROBLEMS AND PROSPECTS
Ahmadova, J. M. A. A. A., & Ibrahimov, S. I. S. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-152 · Cited by 20
Goje, I.-D., Barbulescu, G. I., Ordodi, V. L., Ciobotaru, V. G., Ivan, V. S., Buzaș, R., Tunea, O., Bojin, F. M., & Lighezan, D.-F. (2025) · Pharmaceuticals · doi:10.3390/ph18050681 · Cited by 25
Pharmacogenomics for immunotherapy and immune-related cardiotoxicity
Lal, J. C., Eng, C., & Cheng, F. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa137 · Cited by 21
Chen, D. H., Tyebally, S. M., Mallouppas, M., Roylance, R. R., Spurrell, E. L., Raja, F. A., & Ghosh, A. K. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01446-x · Cited by 21
Subclinical cardiac damage in cancer patients before chemotherapy
Fabiani, I., Panichella, G., Aimo, A., Grigoratos, C., Vergaro, G., Pugliese, N. R., Taddei, S., Cardinale, D. M., Passino, C., Emdin, M., et al. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10151-4 · Cited by 21
Self-citationOliva, S., Puzzovivo, A., Gerardi, C., Allocati, E., Sanctis, V. D., Minoia, C., Skrypets, T., Guarini, A., & Gini, G. (2021) · Cancers · doi:10.3390/cancers14010061 · Cited by 20
Chitturi, K. R., Burns, E. A., Muhsen, I. N., Anand, K., & Trachtenberg, B. H. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01215-1 · Cited by 20
Ho, K. L., Shiels, M. S., Ramin, C. A., Veiga, L. H. S., Chen, Y., de González, A. B., & Vo, J. B. (2022) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkac083 · Cited by 20
Cardiovascular Toxicity and Risk Mitigation with Lung Cancer Treatment
Yegya‐Raman, N., Berlin, E. E., Feigenberg, S. J., Ky, B., & Sun, L. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01387-4 · Cited by 21
Self-citationAttachaipanich, T., Chattipakorn, S. C., & Chattipakorn, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030785 · Cited by 21
Characteristics and Outcomes of Patients with a History of Cancer Recruited to Heart Failure Trials
Dobbin, S. J. H., Shen, L., Petrie, M. C., Packer, M., Solomon, S. D., McMurray, J. J. V., Lang, N. N., & Jhund, P. S. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2818 · Cited by 20
Kersting, D., Mavroeidi, I. A., Settelmeier, S., Seifert, R., Schüler, M., Herrmann, K., Rassaf, T., & Rischpler, C. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264868 · Cited by 20
Riverola, A. P., Morillas, H., Berdejo, J., Pernas, S., Pomares, H., Asiáin, L., Garay, A., Fernández-Ortega, A., Oliveira, A. C., Martinez, E., et al. (2023) · Cancers · doi:10.3390/cancers15245885 · Cited by 21
Cardiovascular disease and stroke following cancer and cancer treatment in older adults
Muhandiramge, J., Zalcberg, J. R., Warner, E. T., Polekhina, G., Gibbs, P., Londen, G. J. V., Bernstein, W. B., Macrae, F., Haydon, A. M., Tie, J., et al. (2024) · Cancer · doi:10.1002/cncr.35503 · Cited by 20
Kadowaki, H., Akazawa, H., Ishida, J., & Komuro, I. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0467 · Cited by 20
Chachaj, A., Matkowski, R., Gröbner, G., Szuba, A., & Dudka, I. (2020) · Diagnostics · doi:10.3390/diagnostics10110936 · Cited by 22
The ESC Cardio-Oncology Guidelines
Sparano, J. A., & Sahni, G. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.10.010 · Cited by 20
Shouval, R., Goldman, A., Flynn, J. R., El‐Moghraby, A., Rehman, M., Devlin, S. M., Corona, M., Landego, I., Lin, R. J., Scordo, M., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19497 · Cited by 19
Koop, Y., Teske, A. J., Wanders, I., Meijer, H. J. M., Kaanders, J. H. A. M., Manintveld, O. C., Hassing, H. C., Vermeulen, H., Maas, A. H. E. M., van Spronsen, D.-J., et al. (2022) · Journal of Cancer Survivorship · doi:10.1007/s11764-022-01163-6 · Cited by 19
Transformational Applications of Human Cardiac Organoids in Cardiovascular Diseases
Xuan, W., Tipparaju, S. M., & Ashraf, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.936084 · Cited by 20
Understanding the Protective Role of Exosomes in Doxorubicin‐Induced Cardiotoxicity
Zhang, G., Yang, X., Su, X., An, N., Yang, F., Li, X., Jiang, Y., & Xing, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/2852251 · Cited by 19
Radiation-Induced Cardiovascular Toxicities
Badiyan, S. N., Puckett, L. L., Vlacich, G. R., Schiffer, W. B., Pedersen, L. N., Mitchell, J. D., & Bergom, C. R. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01012-9 · Cited by 19
Self-citationHussen, N. H., Hasan, A. H., Muhammed, G. O., Yassin, A. Y., Salih, R. R., Esmail, P. A., Alanazi, M. M., & Jamalis, J. (2023) · Current Organic Chemistry · doi:10.2174/1385272827666230423144150 · Cited by 19
Alexandraki, A., Papageorgiou, E., Zacharia, M., Keramida, K., Papakonstantinou, A., Cipolla, C. M., Tsekoura, D., Naka, K. Κ., Mazzocco, K., Mauri, D. N., et al. (2023) · Cancers · doi:10.3390/cancers15133290 · Cited by 19
Self-citationTajstra, M., Dyrbuś, M., Rutkowski, T., Składowski, K., Sosnowska‐Pasiarska, B., Góźdź, S. S., Radecka, B. S., Staszewski, M., Majsnerowska, A., Myrda, K., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14466 · Cited by 19
Ferroptosis-induced Cardiotoxicity and Antitumor Drugs
Beretta, G. L. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230719124453 · Cited by 19
Bisceglia, I., Canale, M. L., Silvestris, N., Gallucci, G., Camerini, A., Inno, A., Camilli, M., Turazza, F. M., Russo, G., Paccone, A., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1223660 · Cited by 21
Self-citationMechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events
Kadowaki, H., Akazawa, H., Ishida, J., & Komuro, I. (2021) · JMA Journal · doi:10.31662/jmaj.2021-0001 · Cited by 19
Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors
Patel, S., Dushenkov, A., Jungsuwadee, P., Krishnaswami, A., & Barac, A. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10024-5 · Cited by 19
Self-citationStrategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?
Kikuchi, R., Shah, N. P., & Dent, S. F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040896 · Cited by 18
Self-citationRole of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis
Éderhy, S., Salem, J., Dercle, L., Hasan, A. S., Chauvet-Droit, M., Nhan, P., Ammari, S., Pinna, B., Redheuil, A. B., Boussouar, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.640985 · Cited by 19
Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer
Altena, R., Hűbbert, L., Kiani, N. A., Wengström, Y., Bergh, J. C. S., & Hedayati, E. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00105-y · Cited by 18
Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients
Stansfeld, A., Radia, U. K., Goggin, C., Mahalingam, P., Benson, C., Napolitano, A., Jones, R. L., Rosen, S. D., & Karavasilis, V. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2124107 · Cited by 18
Wu, Y., Gao, D., Xue, J., & Zuo, Z. (2022) · Biomolecules · doi:10.3390/biom12121788 · Cited by 18
Chemotherapy-related cardiac dysfunction: the usefulness of myocardial work indices
Lisi, D. D., Manno, G., Madaudo, C., Filorizzo, C., Intravaia, R. C. M., Galassi, A. R., Incorvaia, L., Russo, A. D., & Novo, G. (2023) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-023-02897-9 · Cited by 18
Park‐Simon, T., Müller, V., Albert, U., Banys-Paluchowski, M. J., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Ditsch, N. C., Fallenberg, E. M., et al. (2024) · Breast Care · doi:10.1159/000538596 · Cited by 18
Li, X., Lin, Y., Song, L., Huang, J., & Ruan, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1404692 · Cited by 18
ASSESSMENT OF ENTERPRISE EFFICIENCY AND EFFECTIVENESS BOTH ON DOMESTIC AND WORLDWIDE PRACTICE
Mirheydarova, R. R. A. M. A. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-147 · Cited by 17
Salmanova, N. S. N. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-141 · Cited by 17
Alshahrani, A. A., Kontopantelis, E., Morgan, C., Ravindrarajah, R., Martin, G. P., & Mamas, M. A. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003419 · Cited by 21
An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors
Esposito, R., Fedele, T., Orefice, S., Cuomo, V., Prastaro, M., Canonico, M. E., Ilardi, F., Stefano, F. D., Fiorillo, L., Santoro, C., et al. (2021) · Biomolecules · doi:10.3390/biom11060785 · Cited by 18
Cardiac morbidity & mortality in patients with breast cancer
Dhir, A. A., & Sawant, S. P. (2021) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_879_20 · Cited by 17
Lee, S. F., Yip, P. L., Vellayappan, B. A., Chee, C. E., Wong, L. C., Wan, E. Y. F., Chan, E. W., Lee, C.-F., Lee, F. A.-S., & Luque-Fernández, M. Á. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7042 · Cited by 17
Gerodias, F. R., Tan, M. K. C., Guzman, A. D., Bernan, A. P., Locnen, S. A., Apostol-Alday, A., Ybanez, E. J. O., Magno, J. D. A., Lim, A., Junia, A. T., et al. (2022) · Cardiology Research · doi:10.14740/cr1442 · Cited by 17
Cardio-Oncology Recommendations for Pediatric Oncology Patients
Toro, C., Felmingham, B., Jessop, S., Celermajer, D. S., Kotecha, R. S., Govender, D., Hanna, D. M. T., O'Connor, M. J., Manudhane, R., Ayer, J. G., et al. (2022) · JACC Advances · doi:10.1016/j.jacadv.2022.100155 · Cited by 17
Zaborowska-Szmit, M., Szmit, S., Olszyna‐Serementa, M., Badurak, P., Zajda, K., Janowicz-Żebrowska, A., Piórek, A., Knetki‐Wróblewska, M., Jaśkiewicz, P., Płużański, A., et al. (2023) · Cancers · doi:10.3390/cancers15041277 · Cited by 17
The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity
Zhang, X., Gao, Y., Yang, B., Ma, S., Zuo, W., & Wei, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109895 · Cited by 18
Anthracyclines-Induced Cardiac Dysfunction: What Every Clinician Should Know
Ferrera, A., Fiorentini, V., Reale, S., Solfanelli, G., Tini, G., Barbato, E., Volpe, M., & Battistoni, A. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2405148 · Cited by 17
Han, S., Sohn, T. J., Ng, B. P., & Park, C. (2023) · Scientific Reports · doi:10.1038/s41598-023-40552-4 · Cited by 17
Luo, Y., Zeng, Z., Liu, Y., & Liu, A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189008 · Cited by 17
Camilli, M., Ferdinándy, P., Salvatorelli, E., Menna, P., & Minotti, G. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.07.002 · Cited by 18
Lee, S. F., Luque-Fernández, M. Á., Chen, Y., Catalano, P. J., Chiang, C., Wan, E. Y. F., Wong, I. C. K., Chen, M. H., & Ng, A. K. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002737 · Cited by 17
Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies
Bergler-Klein, J. K., Rainer, P. P., Wallner, M., Zaruba, M., Dörler, J., Böhmer, A., Buchacher, T., Frey, M. K., Adlbrecht, C., Bartsch, R., et al. (2022) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02031-0 · Cited by 18
Gherghe, M., Lazăr, A. M., Mutuleanu, M.-D., Bordea, C. I., Ionescu, S. O., Mihăilă, R. I., Petroiu, C., & Stanciu, A. E. (2022) · Cancers · doi:10.3390/cancers15010207 · Cited by 17
Lung Cancer and Cardiovascular Disease
El-Rayes, M., Agmon, I. N., Yu, C., Osataphan, N., Yu, H. A., Hope, A. J., Sacher, A. G., Yu, A. F., Abdel-Qadir, H. M., & Thavendiranathan, P. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.05.003 · Cited by 19
Hsu, Y.-L., Lee, C., Chung, W., Lee, W.-H., Lee, K., Tsai, J.-H., Hsu, H., Yang, S., Loh, Z.-J., Su, P., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3758 · Cited by 18
Increased standardised incidence ratio of cardiovascular diseases among colorectal cancer patients
Hsu, H., Chern, Y., Hsieh, C.-T., Yeh, T., Tsai, M.-C., Wang, C., Hsiao, B., Jhuang, J., Chiang, C., Lee, W., et al. (2022) · International Journal of Colorectal Disease · doi:10.1007/s00384-022-04129-3 · Cited by 16
Vo, J. B., Ramin, C. A., Lawrence, W. R., Barac, A., Ho, K. L., Rhee, J., Veiga, L. H. S., & de González, A. B. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad024 · Cited by 16
Self-citationImmune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology
He, Y., Yu, H., Dai, S., He, M., Ma, L., Xu, Z., Luo, F., & Wang, L. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.01.024 · Cited by 17
El-Sherbeny, W. S., Sabry, N. M., El-Saied, S. B., & Elnagar, B. (2023) · Cardio-Oncology · doi:10.1186/s40959-023-00169-y · Cited by 16
Lisi, D. D., Dessalvi, C. C., Zito, C., Madaudo, C., Manganaro, R., Mercurio, V., Deidda, M., Santoro, C., Penna, C. R. R., Monte, I. P., et al. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102229 · Cited by 17
Theofilis, P., Vlachakis, P. K., Oikonomou, E. K., Drakopoulou, M., Karakasis, P., Apostolos, A., Pamporis, K., Tsioufis, K. P., & Tousoulis, D. (2024) · Biomedicines · doi:10.3390/biomedicines12122914 · Cited by 21
Radiation-induced cardiovascular disease: an overlooked role for DNA methylation?
Sallam, M., Benotmane, M. A., Baatout, S., Guns, P., & Aerts, A. (2021) · Epigenetics · doi:10.1080/15592294.2021.1873628 · Cited by 16
Sueta, D., Kidoh, M., Oda, S., Egashira, K., Yamamoto, E., Kaikita, K., Matsushita, K., Yamamoto, Y., Hirai, T., & Tsujita, K. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-1288 · Cited by 16
Tamargo, J. L., Caballero, R., & Delpón, E. (2022) · Drug Safety · doi:10.1007/s40264-021-01132-5 · Cited by 17
Long-Term Cardiovascular Mortality among 80,042 Older Patients with Bladder Cancer
Guan, T., Su, M., Luo, Z., Peng, W., Zhou, R., Lu, Z., Feng, M., Li, W., Teng, Y., Jiang, Y., et al. (2022) · Cancers · doi:10.3390/cancers14194572 · Cited by 16
Arguelles, O. C., Abdel-Qadir, H. M., Ky, B., Liu, J. E., Lopez‐Mattei, J., Amir, E., & Thavendiranathan, P. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.04.001 · Cited by 16
Self-citationCardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice
Ciappina, G., Colarusso, L., Maiorana, E., Ottaiano, A., Franchina, T., Picone, A., Facchini, G., Barraco, C., Ieni, A., Cusmà-Piccione, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18091399 · Cited by 16
Egashira, K., Sueta, D., Tomiguchi, M., Kidoh, M., Oda, S., Usuku, H., Hidaka, K., Goto‐Yamaguchi, L., Sueta, A., Komorita, T., et al. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100797 · Cited by 15
Tavares, V., Neto, B. V., Vilas-Boas, M. I., Pereira, D., & Medeiros, R. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188778 · Cited by 15
Inequity in care delivery in cardio-oncology: dissecting disparities in underrepresented populations
Patel, S., Suero-Abreu, G., Ai, A., Ramachandran, M. K., Meza, K., & Florez, N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1124447 · Cited by 14
Chemotherapy Related Cardiotoxicity Evaluation—A Contemporary Review with a Focus on Cardiac Imaging
Scalia, I. G., Gheyath, B., Tamarappoo, B. K., Moudgil, R., Otton, J. M., Pereyra, M., Narayanasamy, H., Larsen, C., Herrmann, J., Arsanjani, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133714 · Cited by 19
Self-citationBaldassarre, L. A., Yang, E. H., Cheng, R. K.-H., DeCara, J. M., Dent, S. F., Liu, J. E., Rudski, L., Strom, J. B., Thavendiranathan, P., Barac, A., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa177 · Cited by 15
Self-citationCirculating Biomarkers for Cardiotoxicity Risk Prediction
Gong, F. F., Cascino, G. J., Murtagh, G., & Akhter, N. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00845-0 · Cited by 15
Cardiooncology—dealing with modern drug treatment, long-term complications, and cancer survivorship
de Wall, C., Bauersachs, J. K., & Berliner, D. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10106-x · Cited by 15
Kubota, S., Hara, H., & Hiroi, Y. (2021) · Global Health & Medicine · doi:10.35772/ghm.2021.01024 · Cited by 16
The Importance of Primary Care in Cardio-Oncology
Cehic, D., Sverdlov, A. L., Koczwara, B., Emery, J. D., Ngo, D. T. M., & Thornton‐Benko, E. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00908-2 · Cited by 16
Relationship between Chemotherapy and Atrial Fibrillation: Clinical Case
Арманович, А. А., Mkrtchyan, L., Gevorkyan, A. A., Конончук, Н. Б., Kakturskiy, L., & Jndoyan, Z. (2021) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2021-10-17 · Cited by 15
Shibata, T., Nohara, S., Morikawa, N., Shibao, K., Shinichiro, I. T. O., Shibata, R., Toh, U., Nagafuji, K., Fukami, K., & Fukumoto, Y. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad210 · Cited by 15
Cardiotoxicity of Chemotherapeutic Drugs: An Update and Future Perspectives.
Bannister, C., Cannata, A. N., Bromage, D. I., & McDonagh, T. A. (2022) · PubMed · doi:10.1097/fjc.0000000000001226 · Cited by 11
Immune checkpoint inhibitor-related myositis: from pathophysiology to treatment
Sundarrajan, C., Bhai, S. F., & Dimachkie, M. M. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/q7mdjs · Cited by 17
Multimodality imaging in cardio-oncology: the added value of CMR and CCTA
Lisi, C., Catapano, F., Rondi, P., Figliozzi, S., Monaco, M. L., Brilli, F., Monti, L., & Francone, M. (2023) · British Journal of Radiology · doi:10.1259/bjr.20220999 · Cited by 14
Cardiotoxicity of Agents Used in Patients With Breast Cancer
Zagami, P., Trapani, D., Nicolò, E., Corti, C., Valenza, C., Criscitiello, C., Curigliano, G., & Carey, L. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00494 · Cited by 18
Self-citationFrom Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond
Zhou, Y., Yao, Z., Lin, Y., & Zhang, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070888 · Cited by 15
Brazilian Guideline on Menopausal Cardiovascular Health – 2024
de Oliveira, G. M. M., de Almeida, M. C. C., Artucio, C., Espíndola, L. N., Rivera, M. A. M., Filho, A. L. D. S., Marques-Santos, C., Fernandes, C. E., Albuquerque, C. J. D. M., Freire, C. M. V., et al. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240478i · Cited by 17
Herceptin-Mediated Cardiotoxicity: Assessment by Cardiovascular Magnetic Resonance
Jin, J., Liu, B., & Hothi, S. S. (2022) · Cardiology Research and Practice · doi:10.1155/2022/1910841 · Cited by 17
Therapy-Related Clonal Hematopoiesis
Yura, Y., Cochran, J. D., & Walsh, K. X. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.02.010 · Cited by 14
Women at heart: Introducing gender cardio-oncology
Canale, M. L., Bisceglia, I., Gallucci, G., Russo, G., Camerini, A., Fusco, S. A. D., Paccone, A., Camilli, M., Fiscella, D., Lestuzzi, C., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.974123 · Cited by 14
Bertorello, N., Luksch, R., Bisogno, G., Haupt, R., Spallarossa, P., Cenna, R., & Fagioli, F. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30515 · Cited by 14
Lódi, M., Bánhegyi, V., Bódi, B., Gyöngyösi, A., Kov́acs, Á., Árokszállási, A., Hamdani, N., Fagyas, M., Edes, I. F., Csanádi, Z., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02564-w · Cited by 14
Minotti, G., Menna, P., Camilli, M., Salvatorelli, E., & Levi, R. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2022.02.002 · Cited by 16
Pereyra, M., Farina, J., Scalia, I. G., Roarke, M. C., Mahmoud, A., Masson, R., Wasef, B., Tagle‐Cornell, C., Kenyon, C. R., Abbas, M. T., et al. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.12.017 · Cited by 13
Self-citationAnker, M. S., Mahabadi, A. A., Totzeck, M., Tewes, M., Khan, M. S., Mincu, R. I., Hendgen-Cotta, U. B., Michel, L., Mathew, B., Drescher, O., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf705 · Cited by 13
Koop, Y., Dobbe, L., Maas, A. H. E. M., van Spronsen, D. J., Atsma, F., Messaoudi, S. E., & Vermeulen, H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249067 · Cited by 13
Benefits of β-blockers in cancer treatment
Arif, M., Hardianti, M. S., Tyagita, N., & Safitri, A. H. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2022.0016 · Cited by 13
Rosenfeld, R., Riondino, S., Formica, V., Torino, F., Martuscelli, E., & Roselli, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071059 · Cited by 13
Yaseen, I. F., & Farhan, H. A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.972455 · Cited by 13
Metadata
- Authors
- Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., de Azambuja, E., Zamorano, J. L., Krone, R., Iakobishvili, Z., Carver, J., Armenian, S., Ky, B., Cardinale, D., Cipolla, C. M., Dent, S., & Jordan, K.
- Affiliations
- University of Milan (IT)
- Washington University Medical Center (US)
- University of South Florida (US)
- Lahey Hospital and Medical Center (US)
- Georgetown University (US)
- University of Minnesota (US)
- Mayo Clinic (US)
- University of Kansas Medical Center (US)
- Royal Brompton Hospital (GB)
- Centre Hospitalier Universitaire de Liège (BE)
- University of Chicago (US)
- Vanderbilt University (US)
- Stanford Medicine (US)
- European Institute of Oncology (IT)
- Hospital Universitario Ramón y Cajal (ES)
- Washington University in St. Louis (US)
- Tel Aviv University (IL)
- Hospital of the University of Pennsylvania (US)
- City Of Hope National Medical Center (US)
- University of Pennsylvania (US)
- Duke University (US)
- Heidelberg University (DE)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 31
- Issue
- 2
- Pages
- 171-190
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC8019325
- OpenAlex
- W2999536665
- Cited by
- 1,031
- References
- 221
- Citations by year
- 2026: 108 · 2025: 152 · 2024: 168 · 2023: 189 · 2022: 188 · 2021: 143 · 2020: 83
- FWCI
- 93.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- HF
- Genentech
- Amgen
- Servier
- Pfizer
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Keywords
- cardio-oncology, cardiotoxicity, cancer therapy, heart failure, cardiovascular screening, cardiovascular monitoring, novel cancer therapies, cardiovascular disease in cancer patients
- MeSH terms
- Antineoplastic Agents, Heart Diseases, Humans, Medical Oncology, Neoplasms, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
